Halozyme Therapeutics Inc.

S&P 500

HALO/Healthcare · Biotechnology/NASDAQ

Stock Price

$72.64

Stock Price$72.64P/E24.2MCap8.2BLast update: Jun 26, 2026 at 06:56

Dividend Safety Rating

N/A/ 100

Dividend Safety Rating

HALO does not currently pay a dividend. The Dividend Safety Rating is not applicable for non-dividend stocks.

About Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented recombinant human hyaluronidase enzyme (rHuPH20), enabling subcutaneous administration of injectable biologics like monoclonal antibodies, therapeutic molecules, small molecules, and fluids, improving dispersion and absorption. Key products include Hylenex recombinant for enhancing subcutaneous drug delivery in medical imaging and XYOSTED for testosterone replacement therapy via auto-injector. The ENHANZE drug delivery technology is licensed to partners for co-formulation in treatments targeting oncology, endocrinology, and other areas, with recent approvals for products like RYBREVANT FASPRO, DARZALEX Faspro, and collaborations such as with Takeda for vedolizumab. Halozyme Therapeutics Inc. also expanded its portfolio through the acquisition of Elektrofi, adding high-concentration biologic formulations via Hypercon technology. Operating primarily in the United States with international reach, the company supports biopharmaceutical partners in creating patient-friendly therapies that enhance convenience, tolerability, and adherence. Founded in 1998 and headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a vital role in advancing drug delivery innovations across therapeutic segments.

Dividend Overview

Dividend Yield

0.00%

Annual Dividend

$0.00

Frequency

N/A

Payout Ratio

0.00%

FCF Payout Ratio

0.00%

52-Week Range

$51.06 - $82.22

Earnings & Profitability

HALO earnings per share and net profit margin

Key Dates

Next Ex-Dividend Date

—

Next Payment Date

—

Dividend Growth

3-Year Dividend CAGR

N/A

5-Year Dividend CAGR

N/A

10-Year Dividend CAGR

N/A

3-Year Total Growth

N/A

5-Year Total Growth

N/A

10-Year Total Growth

N/A

Income Calculator

HALO Dividend Calculator

Number of Shares

Total Investment

$7,263.50

Annual Income

$0.00

Quarterly Income

$0.00

Monthly Income

$0.00

Frequently Asked Questions

What is HALO's current dividend yield?

Halozyme Therapeutics Inc. (HALO) currently has a dividend yield of 0.00%, based on a stock price of $72.64 and an annual dividend of $0.00.

When is HALO's next dividend payment date?

HALO's next ex-dividend date is — and the next payment date is —. You must own the stock before the ex-dividend date to receive the upcoming payment.

How much does HALO pay in dividends per year?

Halozyme Therapeutics Inc. pays dividends unknown. Annual dividend data is not yet available.

Has HALO been increasing its dividend?

Halozyme Therapeutics Inc. has grown its dividend at a 5-year CAGR of —.

Is HALO's dividend safe?

Halozyme Therapeutics Inc. has a payout ratio of 0.00%. Its free cash flow payout ratio is 0.00%. A payout ratio below 60% is generally considered sustainable.

How is HALO's Dividend Safety Rating calculated?

The Dividend Safety Rating evaluates Halozyme Therapeutics Inc.'s dividend sustainability across four categories: Payout & Coverage (30%), Balance Sheet (20%), Profitability (20%), and Dividend Track Record (30%). Each metric is rated from "Very Safe" to "Danger" based on industry-standard thresholds, with sector-specific adjustments for healthcare companies. The overall score ranges from 0 to 100.

Want to understand how we rate dividend safety? Read our full methodology

Track HALO Dividends with OnlyDividends

What will HALO actually pay you after taxes? Track every payout, get notified on payment dates, and stop guessing.

This page is not investment advice. The content is for informational purposes only and should not be construed as a recommendation to buy, sell, or hold any security. Always do your own research and consult a qualified financial advisor before making investment decisions.

Financial data, including dividend history, earnings, balance sheet metrics, and the Dividend Safety Rating, is provided for informational purposes only. Data may be delayed or differ from official filings. Past performance does not guarantee future results. Always verify with official sources before making investment decisions.

Market data provided by Twelve Data.